Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $17.83 Consensus PT from Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been assigned an average rating of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $17.83.

A number of research analysts have commented on VYGR shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, August 20th. Wedbush decreased their target price on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th.

Voyager Therapeutics Trading Down 3.6 %

VYGR opened at $6.79 on Thursday. The stock has a 50-day moving average price of $6.67 and a 200-day moving average price of $7.83. Voyager Therapeutics has a 12-month low of $5.71 and a 12-month high of $11.72. The stock has a market capitalization of $369.34 million, a P/E ratio of -135.80 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The company had revenue of $29.58 million during the quarter, compared to analyst estimates of $11.52 million. During the same quarter in the previous year, the company posted ($0.51) EPS. On average, equities research analysts predict that Voyager Therapeutics will post -1.44 EPS for the current year.

Insider Transactions at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the transaction, the insider now owns 86,001 shares of the company’s stock, valued at $500,525.82. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.53% of the stock is owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds have recently bought and sold shares of the business. ADAR1 Capital Management LLC purchased a new stake in shares of Voyager Therapeutics during the 4th quarter valued at about $1,569,000. Vanguard Group Inc. raised its holdings in shares of Voyager Therapeutics by 27.8% during the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after acquiring an additional 702,030 shares in the last quarter. Great Point Partners LLC purchased a new stake in shares of Voyager Therapeutics during the 2nd quarter worth approximately $12,668,000. Armistice Capital LLC raised its holdings in shares of Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after acquiring an additional 528,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Voyager Therapeutics by 3.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock worth $9,702,000 after acquiring an additional 37,144 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.